FMC Corporation has signed a definitive agreement to sell its Epax Omega-3 business to Pelagia AS. The transaction is expected to close by the end of Q3 2017, subject to customary regulatory approvals and closing conditions. Terms of the transaction were not disclosed.
 
“We are pleased to sell our omega-3 business to Pelagia AS, a leading manufacturer of pelagic fish products,” said Eric Norris, president, FMC Health and Nutrition. “We believe Pelagia provides a strong strategic fit for our Epax Omega-3 product line and will complement Pelagia’s existing portfolio.”
 
Pelagia is a producer of pelagic fish and marine protein and oils with factories located in the U.K., Ireland, Denmark, and Norway.